• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Reify Health Raises $30M to Fix The Broken Clinical Trial Ecosystem

by Fred Pennic 08/12/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Reify Health Raises $30M to Fix The Broken Clinical Trial Ecosystem

What You Should Know:

– Reify Health, a clinical trial software provider that digitizes and accelerates clinical trials is announcing a $30 million series B funding round to support the company’s ambitious mission to fix the broken clinical trial ecosystem.  

– The company’s platform, StudyTeam systematically eliminates redundant work across the clinical trial process while generating novel insights that speed up trials.

StudyTeam harmonizes biopharma and research site workflows, introducing a new paradigm for clinical research that brings therapies to patients sooner.


Reify Health, a Boston, MA-based provider of leading cloud-based solutions that connect and empower the clinical trial ecosystem, today announced a $30 million Series B funding round led by Battery Ventures with participation from previous investors including Sierra Ventures and Asset Management Ventures. The funding will drive the continued expansion of Reify’s StudyTeam enrollment solution and accelerate additional platform solutions.

Solutions to Accelerate Clinical Trial Enrollment

Founded in 2012, Reify Health works with an impressive client roster including half of the top-20 biopharmaceutical companies, including Eli Lilly and Amgen and has developed its platform, StudyTeam, to upgrade the systems that healthcare staff at clinical research sites depend on to run trials. By bringing them onto a shared platform with biopharma sponsors, Reify has helped the industry dramatically accelerate clinical trial enrollment and reduce workloads for stakeholders across the ecosystem.

“The life science industry spends over four billion dollars every year on technologies aimed at making clinical trials more efficient,” said Ralph Passarella, CEO and co-founder, Reify Health. “Yet, very little of that investment goes towards technology that helps the frontline healthcare staff who enroll and care for patients. If we want to make clinical trials faster, cheaper, and more predictable, the industry can’t keep building technology that increases efficiency for some but decreases efficiency for those working directly with patients. We decided that we needed to change that.”

StudyTeam systematically eliminates redundant work across the clinical trial process while generating novel insights that speed up trials. For example, staff at research sites spend hours each week manually copying information about patient recruitment and enrollment from their own systems into sponsor logs so that sponsors have the insights they need to manage and optimize enrollment.

With StudyTeam, this hours-long task takes just a few minutes, enabling site staff to spend more time with patients. At the same time, sponsors gain better insights for making real-time enrollment decisions. As a result, StudyTeam accelerates enrollment, on average, by 6 weeks per trial. When 80 percent of trials fail to recruit enough patients on time, this improvement can be seismic.

Patient Recruitment and Enrollment

Reify’s StudyTeam platform is used by 1,800 research sites across 26 countries and by half of the top-20 global biopharma companies, including Eli Lilly and Company and Amgen. The platform has been so effective in improving enrollment dynamics between research sites and sponsors that several top-20 biopharma companies are in the process of implementing the product across their global research portfolios.

“The COVID pandemic has shed light at a global scale how much clinical trial speed matters. While the world sits and waits for COVID-19 vaccines and treatments, we should also remember that patients suffering from numerous conditions such as Alzheimer’s and late stage breast cancer have been waiting on clinical trials for years,” said Michael Lin, co-founder and executive chairman, Reify Health. “At Reify we’ve made it our job to build solutions that streamline work for both research sites and biopharma sponsors so that patients get access to therapies sooner. Doing so has required us to overhaul how we think about solution categories, software business models, and the relationships across the entire clinical trial ecosystem.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |